We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veracyte Stock Surges 117% in a Year: What's Driving the Rally?
Read MoreHide Full Article
Key Takeaways
Veracyte shares surged 117% in a year, outpacing its industry and the S&P 500 composite.
VCYT is advancing TrueMRD, international IVD plans and new tests to support long-term growth.
Veracyte ended Q1 2026 with $439M in cash, no current debt and a current ratio of 9.31.
Veracyte’s (VCYT - Free Report) shares have surged 117% over the past year, showing impressive momentum. It has significantly outperformed the industry’s 11.9% decline and the S&P 500 composite’s 23.9% gain.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
Based in San Francisco, CA, Veracyte offers advanced genomic tests that combine deep scientific, clinical and machine-learning expertise with other capabilities. Presently, the portfolio includes Afirma (for thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer) and Decipher Bladder (bladder cancer), with additional tests in development. The company also has operations in San Diego, CA; Austin, TX; and Haifa, Israel.
Key Catalysts for VCYT’s Growth
Veracyte’s share price is trending upward, prompted by its durable long-term growth strategy. The company prioritizes expansion into minimal residual disease (MR) and recurrence testing, broader international access through IVDs and novel products that address new clinical questions.
In the first quarter, it reiterated that TrueMRD remains the next platform extension and is on track for launch in muscle-invasive bladder cancer by the end of the second quarter, initially focusing on recurrence monitoring following curative-intent therapy. Beyond new tests, Veracyte also advanced its international strategy, with ongoing development efforts aimed at offering Decipher and Prosigna as future in vitro diagnostic (IVD) tests outside the United States.
Investors are also focused on the company’s comprehensive Afirma solution. In the first quarter of 2026, Afirma volumes increased about 12% year over year to approximately 17,200 tests and revenues rose 21%. It expects Afirma revenue growth in the high single digit to low double-digit range for full-year 2026, supported by workflow improvements and continued demand across the customer base.
Veracyte exited the first quarter of 2026 with cash and cash equivalents of $439 million and no current debt, reflecting strong solvency. The company’s ability to cover near-term obligations is further supported by a strong current ratio of 9.31. Consistent with the past quarters, it did not report any long-term debt at the end of the quarter under review.
Image Source: Zacks Investment Research
Factors That May Offset VCYT’s Gains
Veracyte’s operations remain exposed to macroeconomic factors, including inflation, interest rate volatility, foreign exchange fluctuations and evolving international trade policies and government actions relating to tariffs. The ongoing conflict in the Middle East and related conditions in and around Israel may disrupt the company’s Haifa operations tied to the C2i acquisition.
VCYT operates in markets where genomic diagnostics adoption is advancing and competitors continue to invest in alternative methods and broader test menus. Competitive intensity can also show up through litigation.
A Glance at VCYT’s Estimates
In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share (EPS) has remained unchanged at $1.87.
Revenues are projected to grow 12.4% to $581.1 million in 2026, while the same for 2027 is expected to reach $640.7 million (up 10.3%).
Key Pick
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
View the Zacks #1 Rank List
Image: Bigstock
Veracyte Stock Surges 117% in a Year: What's Driving the Rally?
Key Takeaways
Veracyte’s (VCYT - Free Report) shares have surged 117% over the past year, showing impressive momentum. It has significantly outperformed the industry’s 11.9% decline and the S&P 500 composite’s 23.9% gain.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
Based in San Francisco, CA, Veracyte offers advanced genomic tests that combine deep scientific, clinical and machine-learning expertise with other capabilities. Presently, the portfolio includes Afirma (for thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer) and Decipher Bladder (bladder cancer), with additional tests in development. The company also has operations in San Diego, CA; Austin, TX; and Haifa, Israel.
Key Catalysts for VCYT’s Growth
Veracyte’s share price is trending upward, prompted by its durable long-term growth strategy. The company prioritizes expansion into minimal residual disease (MR) and recurrence testing, broader international access through IVDs and novel products that address new clinical questions.
In the first quarter, it reiterated that TrueMRD remains the next platform extension and is on track for launch in muscle-invasive bladder cancer by the end of the second quarter, initially focusing on recurrence monitoring following curative-intent therapy. Beyond new tests, Veracyte also advanced its international strategy, with ongoing development efforts aimed at offering Decipher and Prosigna as future in vitro diagnostic (IVD) tests outside the United States.
Investors are also focused on the company’s comprehensive Afirma solution. In the first quarter of 2026, Afirma volumes increased about 12% year over year to approximately 17,200 tests and revenues rose 21%. It expects Afirma revenue growth in the high single digit to low double-digit range for full-year 2026, supported by workflow improvements and continued demand across the customer base.
Veracyte exited the first quarter of 2026 with cash and cash equivalents of $439 million and no current debt, reflecting strong solvency. The company’s ability to cover near-term obligations is further supported by a strong current ratio of 9.31. Consistent with the past quarters, it did not report any long-term debt at the end of the quarter under review.
Image Source: Zacks Investment Research
Factors That May Offset VCYT’s Gains
Veracyte’s operations remain exposed to macroeconomic factors, including inflation, interest rate volatility, foreign exchange fluctuations and evolving international trade policies and government actions relating to tariffs. The ongoing conflict in the Middle East and related conditions in and around Israel may disrupt the company’s Haifa operations tied to the C2i acquisition.
VCYT operates in markets where genomic diagnostics adoption is advancing and competitors continue to invest in alternative methods and broader test menus. Competitive intensity can also show up through litigation.
A Glance at VCYT’s Estimates
In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share (EPS) has remained unchanged at $1.87.
Revenues are projected to grow 12.4% to $581.1 million in 2026, while the same for 2027 is expected to reach $640.7 million (up 10.3%).
Key Pick
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.